Data Insights

KITE-363 by Gilead Sciences for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval

KITE-363 is under clinical development by Gilead Sciences and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...

Likelihood of Approval and Phase Transition Success Rate Model - KITE-363 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

Data Insights

Brexucabtagene autoleucel by Gilead Sciences for Refractory Acute Myeloid Leukemia: Likelihood of Approval

Brexucabtagene autoleucel is under clinical development by Gilead Sciences and currently in Phase II for Refractory Acute Myeloid Leukemia. According...

Likelihood of Approval and Phase Transition Success Rate Model - Brexucabtagene Autoleucel in Refractory Acute Myeloid Leukemia

Data Insights

Brexucabtagene autoleucel by Gilead Sciences for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Brexucabtagene autoleucel is under clinical development by Gilead Sciences and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According...

Likelihood of Approval and Phase Transition Success Rate Model - Brexucabtagene Autoleucel in Chronic Lymphocytic Leukemia (CLL)

Data Insights

Brexucabtagene autoleucel by Gilead Sciences for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

Brexucabtagene autoleucel is under clinical development by Gilead Sciences and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute...

Likelihood of Approval and Phase Transition Success Rate Model - Brexucabtagene Autoleucel in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Data Insights

Brexucabtagene autoleucel by Gilead Sciences for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval

Brexucabtagene autoleucel is under clinical development by Gilead Sciences and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute...

Likelihood of Approval and Phase Transition Success Rate Model - Brexucabtagene Autoleucel in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

Data Insights

Axicabtagene ciloleucel by Gilead Sciences for Refractory Acute Myeloid Leukemia: Likelihood of Approval

Axicabtagene ciloleucel is under clinical development by Gilead Sciences and currently in Phase II for Refractory Acute Myeloid Leukemia. According...

Likelihood of Approval and Phase Transition Success Rate Model - Axicabtagene Ciloleucel in Refractory Acute Myeloid Leukemia

Data Insights

Axicabtagene ciloleucel by Gilead Sciences for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Axicabtagene ciloleucel is under clinical development by Gilead Sciences and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL)....

Likelihood of Approval and Phase Transition Success Rate Model - Axicabtagene Ciloleucel in Refractory Chronic Lymphocytic Leukemia (CLL)

Data Insights

Axicabtagene ciloleucel by Gilead Sciences for Burkitt Lymphoma: Likelihood of Approval

Axicabtagene ciloleucel is under clinical development by Gilead Sciences and currently in Phase II for Burkitt Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Axicabtagene Ciloleucel in Burkitt Lymphoma

Data Insights

Axicabtagene ciloleucel by Gilead Sciences for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Axicabtagene ciloleucel is under clinical development by Gilead Sciences and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According...

Likelihood of Approval and Phase Transition Success Rate Model - Axicabtagene Ciloleucel in Chronic Lymphocytic Leukemia (CLL)

Data Insights

Axicabtagene ciloleucel by Gilead Sciences for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

Axicabtagene ciloleucel is under clinical development by Gilead Sciences and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute...

Likelihood of Approval and Phase Transition Success Rate Model - Axicabtagene Ciloleucel in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Data Insights

Axicabtagene ciloleucel by Gilead Sciences for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval

Axicabtagene ciloleucel is under clinical development by Gilead Sciences and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute...

Likelihood of Approval and Phase Transition Success Rate Model - Axicabtagene Ciloleucel in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

Data Insights

KITE-363 by Gilead Sciences for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

KITE-363 is under clinical development by Gilead Sciences and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - KITE-363 in Diffuse Large B-Cell Lymphoma

Data Insights

Brexucabtagene autoleucel by Gilead Sciences for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval

Brexucabtagene autoleucel is under clinical development by Gilead Sciences and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - Brexucabtagene Autoleucel in Primary Mediastinal B-Cell Lymphoma

Data Insights

KITE-222 by Gilead Sciences for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According...

Likelihood of Approval and Phase Transition Success Rate Model - KITE-222 in Refractory Chronic Lymphocytic Leukemia (CLL)

Data Insights

KITE-222 by Gilead Sciences for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval

KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - KITE-222 in Primary Mediastinal B-Cell Lymphoma

Data Insights

KITE-222 by Gilead Sciences for Burkitt Lymphoma: Likelihood of Approval

KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Burkitt Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - KITE-222 in Burkitt Lymphoma

Data Insights

KITE-222 by Gilead Sciences for Mantle Cell Lymphoma: Likelihood of Approval

KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - KITE-222 in Mantle Cell Lymphoma

Data Insights

KITE-222 by Gilead Sciences for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According to...

Likelihood of Approval and Phase Transition Success Rate Model - KITE-222 in Chronic Lymphocytic Leukemia (CLL)

Data Insights

KITE-222 by Gilead Sciences for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval

KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...

Likelihood of Approval and Phase Transition Success Rate Model - KITE-222 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

Data Insights

KITE-222 by Gilead Sciences for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - KITE-222 in Diffuse Large B-Cell Lymphoma